摘要
目的:探讨帕利哌酮缓释片对精神分裂症急性期体质量、血糖、血脂等影响。方法:入组精神分裂症住院患者62例,进行8周、开放性、帕利哌酮缓释片单组治疗研究,测定治疗前及4,8周末PANSS、CGI-s及体重、血脂、血糖等。结果:帕利哌酮缓释片治疗8周末,体质量和腰围轻度增加(P<0.05),4周末血糖轻微下降(P<0.05)。血脂在治疗前后无显著性改变(P≥0.05),治疗后PANSS总分显著性下降(P<0.05),8周有效率77.36%,主要有抗胆碱能反应等轻中度不良事件。结论:帕利哌酮缓释片对精神分裂症急性期体质量、血糖等影响较轻,不影响血脂,是一种安全、有效的新药。
Objective ： To explore the effect of paliperidone extended-release tablets （paliperidone ER） on body weight, blood lipids and blood glucose of schizophrenia inpatients. Methods： This was a 8-week, open, single treatment group study. A total of 62 acute schizophrenia inpatients were enrolled. The body weight, blood glucose, blood lipids, PANSS, and CGI-s before and after 4 and 8 weeks of paliperidone treatment were measured Results ： The body weight and waist circumference of the schizophrenia patients increased significantly （P 〈 0.05） after 8 weeks of paliperidone treatment compared with that before treatment, while the blood glucose decreased slightly （P 〈 0.05） after 4 weeks of paliperidone treatment compared with that before treatment. Blood lipids had no difference among the baseline value and 4 and 8 weeks of treatment（P≥0.05）. PANSS total scores decreased significantly AEs includi after treatment（P 〈 0.05） , and the effective rate was 77.36% after 8 weeks of treatment. The main ng anti-cholinergic response were slight or moderate. Conclusion： Paliperidone treatment can cause slight changes of body weight and blood glucose of schizophrenia inpatients, while has no influence on blood lipids paliparidone ER is an effective and safe new drug.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2013年第20期2405-2409,共5页
Chinese Journal of New Drugs
关键词
帕利哌酮缓释片
体质量
血糖
血脂
精神分裂症
paliperidone ER
body weight
blood glucose
blood lipids
schizophrenia
